CompScripts

Study: Face Mask Use for Short Time After Hitting COVID-19 Vaccine Targets Is Beneficial

Maintaining face mask use in public indoor spaces and on public transportation for at least 2 weeks after COVID-19 vaccination targets are met, with a minimum of 70% coverage, cuts costs and saves lives, according to the results of a modelling study published in The Lancet Public Health.

https://ryze.ly/7d1b2b29

Study: Face Mask Use for Short Time After Hitting COVID-19 Vaccine Targets Is Beneficial Simulations of disease spread show that wearing masks for at least 2 weeks after achieving goal of a minimum of 70% population coverage saves money and reduces deaths and hospitalizations.

Clincial Trials Show Niraparib Improves PFS With Tolerable Safety Profile Following Response to Platinum-based Chemotherapy in Ovarian Cancer

Niraparib (Zejula; Zai Lab Limited) showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a tolerable safety profile following a response to platinum-based chemotherapy regardless of biomarker status, according to the results of the phase 3 PRIME study presented at the Society of Gynecologic Oncology (SGO) annual meeting.1 The trial assessed niraparib as maintenance therapy in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, which were collectively termed ovarian cancer for the purposes of the study.

https://ryze.ly/0ca44af7

Clincial Trials Show Niraparib Improves PFS With Tolerable Safety Profile Following Response to Platinum-based Chemotherapy in Ovarian Cancer Niraparib shows promise in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.